{"title":"研发对抗血友病的武器","authors":"P. Mannucci","doi":"10.4081/btvb.2023.64","DOIUrl":null,"url":null,"abstract":"Very few rare diseases have witnessed the gigantic progress in patient care that took place for the hemophilias in the last 20 years. The first landmark was in the 1990s, when recombinant DNA technology afforded the industrial production, regulatory approval and commercialization of an array of factor VIII (FVIII) and factor IX (FIX) products, potentially available in unlimited quantity, efficacious and free from the risk of transmission of such bloodborne infections as HIV and the hepatitis virus B and C [...].","PeriodicalId":186928,"journal":{"name":"Bleeding, Thrombosis, and Vascular Biology","volume":"87 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Growing weapons to fight hemophilia\",\"authors\":\"P. Mannucci\",\"doi\":\"10.4081/btvb.2023.64\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Very few rare diseases have witnessed the gigantic progress in patient care that took place for the hemophilias in the last 20 years. The first landmark was in the 1990s, when recombinant DNA technology afforded the industrial production, regulatory approval and commercialization of an array of factor VIII (FVIII) and factor IX (FIX) products, potentially available in unlimited quantity, efficacious and free from the risk of transmission of such bloodborne infections as HIV and the hepatitis virus B and C [...].\",\"PeriodicalId\":186928,\"journal\":{\"name\":\"Bleeding, Thrombosis, and Vascular Biology\",\"volume\":\"87 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-02-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bleeding, Thrombosis, and Vascular Biology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4081/btvb.2023.64\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bleeding, Thrombosis, and Vascular Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4081/btvb.2023.64","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Very few rare diseases have witnessed the gigantic progress in patient care that took place for the hemophilias in the last 20 years. The first landmark was in the 1990s, when recombinant DNA technology afforded the industrial production, regulatory approval and commercialization of an array of factor VIII (FVIII) and factor IX (FIX) products, potentially available in unlimited quantity, efficacious and free from the risk of transmission of such bloodborne infections as HIV and the hepatitis virus B and C [...].
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
